Market revenue in 2023 | USD 1,806.4 million |
Market revenue in 2030 | USD 2,782.1 million |
Growth rate | 6.4% (CAGR from 2023 to 2030) |
Largest segment | Api |
Fastest growing segment | API |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | API, Drug Product |
Key market players worldwide | Lonza Group Ltd, Thermo Fisher Scientific Inc, Labcorp Holdings Inc, Catalent Inc, Wuxi AppTec Co Ltd, Siegfried Holding AG, Nipro Corp, Piramal Pharma Solutions, Recipharm Venture Fund, CordenPharma, Cambrex, Bushu Pharmaceuticals, Seqens |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pharmaceutical cdmo market will help companies and investors design strategic landscapes.
Api was the largest segment with a revenue share of 80.95% in 2023. Horizon Databook has segmented the Sweden pharmaceutical cdmo market based on api, drug product covering the revenue growth of each sub-segment from 2018 to 2030.
The Swedish pharmaceutical market is highly competitive, with multinational pharmaceutical companies and domestic manufacturers operating locally. The market is driven by innovation, with a significant number of clinical trials taking place in Sweden.
The country has a strong R&D infrastructure, with several universities and research institutes collaborating with the pharmaceutical industry to drive innovation & develop new therapies. Overall, the Swedish pharmaceutical market offers opportunities for domestic and international companies.
However, navigating the complex regulatory landscape is crucial for success. Furthermore, the increasing demand for pharmaceutical CDMO services in Sweden can be attributed to the growing approvals granted by the Swedish government for advanced manufacturing lines.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden pharmaceutical cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Sweden pharmaceutical cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account